{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["184(7)"],"submitter":["Ji H"],"pubmed_abstract":["<h4>Importance</h4>Previous studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA1c), and improve insulin resistance in people with type 2 diabetes.<h4>Objective</h4>To evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities.<h4>Design, setting, and participants</h4>This multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023. Individuals aged 18 to 70 years with IGT and multiple metabolic abnormalities were enrolled.<h4>Intervention</h4>Particip"],"journal":["JAMA internal medicine"],"pagination":["727-735"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11148787"],"repository":["biostudies-literature"],"pubmed_title":["Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial."],"pmcid":["PMC11148787"],"pubmed_authors":["Fang H","Hu S","Shi M","Hu X","Sa R","Zhang H","Zhang M","Zhang L","Zhang R","Peng Z","Piao C","Guo H","Wan J","Su Y","Zhang C","Qiao G","Xu Q","Feng Y","Zheng Q","Xu J","Xu T","Hu L","Sang L","Han X","Pang Y","Dai Y","Zhao X","Zhao L","Zhao S","Zhao Q","Wei G","Cheng H","Tian M","Fan Y","Zhou R","Xiao X","Zhou T","Tong X","You Q","Zhou Y","Dai L","Tian W","Yu A","Qin G","Han J","Hong W","Shi J","Zang C","Ye J","Wang B","Wu Q","Yue L","Huang N","Gao H","Huang L","Wang H","Wang J","Wang L","Shang M","Lian F","Sun F","Chen X","Wang X","Sun G","Kuang H","Wang Y","Chen R","Li H","Xie W","Yang J","Sheng Y","Li J","Chen L","Li F","Yang B","Sun W","Li K","Sun X","Li L","Li M","Li Z","Lun L","Li S","Lu J","Yao C","Gao W","Liu H","Jing J","Liu L","Ma L","Cai M","Niu W","Cai G","Liu X","Liu Y","Zheng J","Song P","FOCUS Trial Committees and Investigators","Jia Z","Pan X","Yan L","Yin W","Ji H","Song A","Song G","Zhang W","Lai Y","Juan Y","Luo J","Zhang Y","Zhang X","Fang Q","Gan X","Cai X"],"additional_accession":[]},"is_claimable":false,"name":"Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.","description":"<h4>Importance</h4>Previous studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA1c), and improve insulin resistance in people with type 2 diabetes.<h4>Objective</h4>To evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities.<h4>Design, setting, and participants</h4>This multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023. Individuals aged 18 to 70 years with IGT and multiple metabolic abnormalities were enrolled.<h4>Intervention</h4>Particip","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T12:54:18.672Z","creation":"2025-04-04T12:54:18.672Z"},"accession":"S-EPMC11148787","cross_references":{"pubmed":["38829648"],"doi":["10.1001/jamainternmed.2024.1190"]}}